WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Addicted to hunting lodges, horses and endless parties, the freeWhat is happening with the NZ housing market this week?Kate will 'lean on' her trusted nanny Maria Borrallo as she recovers from abdominal surgeryThe abandoned villa in Italy where Edward VII's mistress, Alice Keppel liked to sun herselfPrince William spotted on 'lowMeghan Markle purchased pair of £1990 diamond earrings from Dragons' Den hopefulsLoosening building products red tape 'good first step'Sophie Wessex and daughter Lady Louise are Queens of the royal handWhy is bitcoin halvingHamas delegation leaves Gaza truce talks in Cairo without deal
2.706s , 6499.0703125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Insight news portal